Analyst: Lucentis Set To Grab 'Majority' Of Market For AMD

Lucentis is on the march. Again.

Last week, Genentech Inc. released the detailed data from the Phase III MARINA study of Lucentis (ranibizumab) in wet age-related macular degeneration, confirming interim data disclosed in May - but the news got even better.